Everett, S. A., Coburn, C. A., Doroodian, S. D., Everett, K. H., Zuck, M. D., Zuck, M. V. (2026). Clinical genomic and quantitative IHC–driven target identification to enable precision, tumor-selective activation of SynchroLINK T2X antibody-drug conjugates.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e15043